APPLIED DNA SCIENCES INC APDN Income Statement

Applied dna sciences inc (APDN)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Jun'10
Revenues:
Total revenues
552	633	1,672	2,053	778	884	1,195	1,016	1,043	647	-	1,797	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product revenues
-	-	-	-	-	-	-	-	-	-	-	-	689	704	1,370	295	178	693	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Service revenues
-	-	-	-	-	-	-	-	-	-	-	-	216	198	265	357	394	630	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenues
-	-	-	-	-	-	-	-	-	-	-	-	905	903	1,636	652	573	1,324	3,980	2,267	1,518	1,241	645	841	637	597	729	644	344	317	290	528	518	516	280	229	140	317	170
Cost of revenues
179	232	320	270	133	153	250	252	372	331	272	232	297	274	552	180	253	184	-	129	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating expenses:
Selling, general and administrative
2,285	2,373	2,259	2,407	2,528	3,082	3,571	2,882	1,996	2,593	2,790	3,402	3,230	3,900	2,539	2,576	2,522	3,169	2,614	3,222	2,901	4,671	3,157	2,948	3,297	3,845	2,682	3,240	2,754	2,521	1,886	1,752	1,824	2,152	3,859	1,580	1,619	1,329	2,529
Research and development
703	564	886	719	651	709	716	625	669	740	524	603	635	518	805	1,149	1,073	672	1,458	466	373	278	215	266	359	459	183	184	176	147	158	99	96	78	107	47	92	20	18
Depreciation and amortization
66	75	70	87	97	135	121	122	145	157	400	161	163	161	148	168	170	218	136	121	123	109	116	113	106	105	215	62	21	20	13	103	98	98	90	91	91	92	92
Total operating expenses
3,055	3,012	3,216	3,214	3,277	3,926	4,410	3,630	2,811	3,490	3,715	4,167	4,029	4,581	3,493	3,894	3,766	4,060	4,210	3,810	3,397	5,059	3,490	3,328	3,764	4,410	3,081	3,488	2,952	2,689	2,057	1,955	2,019	2,329	4,057	1,720	1,804	1,442	2,640
LOSS FROM OPERATIONS
-2,682	-2,611	-1,863	-1,431	-2,632	-3,196	-3,465	-2,866	-2,139	-3,174	-2,842	-2,602	-3,421	-3,953	-2,409	-3,422	-3,447	-2,920	-485	-1,672	-1,878	-3,817	-2,844	-2,487	-3,127	-3,812	-2,352	-2,843	-2,608	-2,372	-1,767	-1,427	-1,501	-1,812	-3,776	-1,490	-1,663	-1,124	-2,470
Other (expense) income:
Interest income, net
-	-	-	-	-	-	-	-	-	-	-	0	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense (including related parties interest of $25,840 and $49,310 for the three and six months ended March 31, 2019, respectively)
-29	-29	-55	-38	-37	-31	-	-	-	-	-	-	-	-	1	2	4	2	3	5	0	-31	-11	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-
Other income (Note C)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Interest income (expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	42	597	640	664	934	219	126
Other expense, net
-239	-22	-11	-8	-16	-6	-0	-21	-6	-9	-11	-8	-8	-9	-6	52	-24	-8	-14	-3	-6	-3	-4	52	-79	155	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on conversion of Promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,961	0	0	-980	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	519	6,332	-	-	-	-	-	-	-	-	-
Loss on change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-2,994	755	515	455	-2,634	-	707	-	-	-	-	-	-	-	-	-	-	-
Loss before provision for income taxes
-2,950	-2,662	-1,218	-1,477	-2,686	-3,234	-3,475	-2,887	-2,146	-3,183	-2,854	-2,610	-3,428	-3,961	-2,415	-3,367	-3,467	-2,926	-496	-1,670	-1,885	-7,828	-2,105	-1,919	-2,750	-6,291	-3,718	-2,135	-3,127	-8,704	-1,767	-1,429	-1,543	-2,409	-4,417	-2,154	-2,598	-1,344	-2,596
Provision for income taxes
0	0	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NET LOSS
-2,950	-2,662	-	-	-2,686	-3,234	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,596
Less: Net (income) loss attributable to noncontrolling interest
1	-0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NET LOSS attributable to Applied DNA Sciences, Inc.
-2,952	-2,662	-1,224	-1,477	-2,686	-3,234	-3,475	-2,887	-2,146	-3,183	-2,854	-2,610	-3,428	-3,961	-2,415	-3,367	-3,467	-2,926	-496	-1,670	-1,885	-7,828	-2,105	-1,919	-2,750	-6,291	-3,718	-2,135	-3,127	-8,704	-1,767	-1,429	-1,543	-2,409	-4,417	-2,154	-2,598	-1,344	-
Deemed dividend related to warrant modifications
0	-2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NET LOSS applicable to common stockholders
-2,952	-2,665	-	-	-2,686	-3,234	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss per share applicable to common stockholders-basic and diluted
-0.79	-1.12	-2.18	-0.04	-3.22	-4.25	-15.57	-0.10	-0.07	-0.12	-0.10	-0.10	-0.13	-0.16	-0.10	-0.14	-0.14	-0.13	0.07	-0.08	-0.11	-0.51	-0.15	-0.14	-0.20	-0.48	-1.50	0.00	0.00	-0.01	-0.74	0.00	0.00	0.00	-0.01	-0.01	-0.01	0.00	-0.01
Weighted average shares outstanding-basic and diluted (in shares)
3,758	2,380	-36,022	38,113	834	761	-84,948	30,112	30,112	27,674	27,363	26,374	26,351	25,427	24,082	24,075	24,072	22,542	21,489	21,444	17,362	15,456	13,857	13,569	13,470	13,164	-2,004,541	721,142	680,399	649,922	-1,630,427	594,931	583,619	490,282	-	351,962	351,395	-	-
Weighted average shares outstanding-Basic and fully diluted (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	349,153	301,362
Product
Total revenues
197	237	1,302	392	119	321	597	393	486	350	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Service
Total revenues
354	395	370	1,660	659	562	597	622	557	297	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-